Loading...
•
Sep 30, 2024
Akoya Q3 2024 Earnings Report
Akoya's third-quarter performance fell short of expectations due to capital equipment purchase constraints, but the company improved its gross margin and reduced operating expenses.
Key Takeaways
Akoya Biosciences reported a decrease in revenue for the third quarter of 2024 compared to the previous year, but improved its gross margin and reduced operating expenses. The company is focused on long-term growth and profitability, and is evaluating strategic alternatives.
Revenue was $18.8 million, a 25% year-over-year decrease.
Gross margin improved to 62.3% from 60.6% in the prior year.
Operating expenses decreased by 25% year-over-year to $20.1 million.
Loss from operations improved by 28% year-over-year to $8.3 million.
Akoya
Akoya
Akoya Revenue by Segment
Revenue by Segment
Product Revenue
CapyFin.com Forward Guidance
Akoya expects revenue for the full year 2024 to be in the range of $80 million to $85 million.